Abstract 4558
Background
Response of desmoid tumors (DT) to chemotherapy (CT) is evaluated according to RECIST criteria in daily practice and clinical trials. However, MRI demonstrates early change in heterogeneity in responding tumor, due to decrease in cellular area and increase in fibro-necrotic content, before dimensional response. Heterogeneity can be quantified through radiomics approach. Aim was to develop radiomics-based response criteria and to compare their performances with usual criteria.
Methods
43 patients (28 women, median age: 38.2) were prospectively included in this ancillary multicentre study of a randomized phase II trial (NCT01876082) as they presented with progressive DT, contrast-enhanced MRI at baseline (MRI-0) and early evaluation (3 months later, MRI-1). After signal intensities normalization, voxel size standardization and segmentation of whole DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D-radiomics features (RF) were extracted. Using least absolute shrinkage and selection operator with Cox regression model and cross validation, a radiomics score based on selected and weighted RF was generated. The performances of prognostic models based on radiomics score, RECIST, mRECIST, EASL, Cheson, Choi and modified-Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS) were assessed with concordance-index. All the results were adjusted for ECOG performance status, initial tumor volume, prior CTs, current CT and B-catenin mutation. Usual response criteria were evaluated in both disease control and objective response settings.
Results
There were 11 progressions. The radiomics score included 4 variables (1 baseline RF and 3 delta-RF). A high radiomics score indicated a poorer prognosis. The radiomics score significantly correlated with PFS (adjusted hazard ratio = 3.39, 95%CI = [1.47-7.79], p = 0.0043) while none of the usual response criteria was (range of p-values = [0.166-0.750]). The prognostic model based on radiomics score had the highest concordance-index (0.794, 95%CI = [0.678-0.910]).
Conclusions
Quantifying heterogeneity with MRI at baseline and its early change through a dedicated radiomics score can improve the response evaluation for DT treated with CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Antoine Italiano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract